Advertisement

Topics

Will biosimilars revolutionise the future of health?By: Harriet Lewis, Medicines Optimisation Lead of the ABPI

05:00 EDT 17 Aug 2017 | Drug Discovery Today

The ABPI represents UK-based pharma companies researching the newest and most innovative medicines. Our members make both originator biological medicines and make biosimilar medicines so, for want of a better word, we have a foot in both camps.

Original Article: Will biosimilars revolutionise the future of health?By: Harriet Lewis, Medicines Optimisation Lead of the ABPI

NEXT ARTICLE

More From BioPortfolio on "Will biosimilars revolutionise the future of health?By: Harriet Lewis, Medicines Optimisation Lead of the ABPI"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...